Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,650.00
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 83.00 (5.03%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chief executives and the itch to quit

Thu, 16th May 2013 07:04

By Andrew Callus

LONDON, May 16 (Reuters) - On approaching his 60th birthdaythis year, long-serving Tullow Oil boss Aidan Heaveytold staff he felt "like two 30 year-olds".

A handful of recent shock departures by 50-something chiefexecutives at European blue chip companies - none of them underany obvious pressure to quit - suggest some of his peers eitherlack that vigour, or want to channel it elsewhere.

Peter Voser is giving up one of the world's most challengingCEO roles at Royal Dutch/Shell next year, before his55th birthday, in pursuit of a "lifestyle change".

Swiss engineering group ABB's 55-year old boss Joe Hogan is also going, for "private reasons". Pierre-OlivierBeckers, 53, is walking out on Belgian retailer Delhaize, and Paul Walsh, 57, is waving goodbye to drinksmultinational Diageo.

All four are about average European CEO age.

While the rising financial rewards of running a modernmultinational have been well publicised, executive recruiterssay the pressures of the job have also been ratcheted up inrecent years, and not just because of the tough economic times.

"The reality is it's gruelling. It's really tough, and therecomes a point where you don't want to do it any more," said IanButcher, who headhunts board-level and senior executives for MWMConsulting.

"The quarterly reporting, the governance, the regulatoryaspects, it just becomes very wearing - the level of scrutiny,the pace at which things are moving, the short-term nature ofhow people look at any given situation. Even over the past fiveyears these things have made CEO a tougher position to hold, andthe travel that people have to undertake in these jobs - it'sjust something they run out of steam on."

Some recent early retirees, while still well short oftraditional retirement age, also got to the top spot early.

"They're still in their early fifties, with energy and adesire to do something, but they want to do something different,something quite significantly different sometimes," saysButcher.

Voser fits that bill. He has no plans to collect well-paidchairmanships and non-executive directorships, as many ex-CEOshave done in the past. Former Tesco chief Terry Leahyhas also resisted that gravy train since he left two years ago.

As for the early starters, executive search industryprofessionals point at people like Andrew Witty, the CEO ofGlaxoSmithKline, who took on the job aged 44 in 2008 andwould have to stay in harness for another decade to reach 60 inthe role.

Blue-chip bosses as young as Witty are still rare, but overa quarter of Europe's current crop have less than two years inthe job, and more than half have less than four, according todata from executive search specialists BoardEx.

MEDIAN CEO AGE IS 55 YEARS

The BoardEx data, collected for Reuters from 238 companiesin the main stock indexes of Germany, Britain, France, Spain,Italy, Belgium, the Netherlands and Denmark, puts the median CEOage at 55, and the median tenure at four years. Only 16 percentof the group have held on for 10 years and more.

The longest serving of them is Martin Gilbert of the Britishfund Aberdeen Asset Management. Though younger, at 57,Gilbert pips the 28.3-year tenure of Tullow's double thirtyyear-old Heavey, with 29.8 years at the helm.

There are 17 top European CEOs who have been in the job forless than six months, and the youngest of the 225 in the groupfor whom ages were available is Vitaly Nesis, 37, who runsPolymetal International, the London-listed Russianprecious metals miner.

While the recent spate of quitters are looking for somethingelse to do, there are still some who appear to want nothing but.

In the BoardEx group there are four over 70, and the oldestby eight years is Albert Frere, CEO of Group Bruxelles Lambert.

Perhaps some linger on for fear that the pension pot isstill a little light. Frere will have put such qualms behind himlong ago. At 87, he is Belgium's richest man.

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.